Status and phase
Conditions
Treatments
About
Combogesic® 325 contains a combination of ibuprofen and acetaminophen. The purpose of this study is to compare the pain relief effects of Combogesic® 325mg and acetaminophen and to evaluate the safety of Combogesic® 325mg in adolescents between the ages of 12 and <18 years.
What will the study involve for participants?
Participants will be randomly allocated to one of 3 treatment groups:
Participants will take 3 tablets every 6 hours with a maximum of 4 doses in 24 hours
Participants and study doctor will be blinded to the treatment group
If pain is not sufficiently controlled, opioids may be used as supplementary pain relief at the discretion of the study doctor.
Participants will complete a patient diary to assess their pain
Participants will rate the study drug at the end of the treatment.
It is expected that Combogesic® tablets (either 2 or 3 tablets per dose) will provide a greater reduction in pain compared to acetaminophen (1000 mg) treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Has taken any NSAID or acetaminophen containing drug products within 5 half-lives prior to the initial dose of study drug.
Hypersensitivity to opioids, NSAIDs or acetaminophen or a history of severe/serious drug reaction to NSAIDs or acetaminophen.
Pregnant or lactating females Known to be pregnant or possibly pregnant.
Sexually active females of childbearing potential not using adequate contraception* and sexually active males not using adequate contraception**
Women of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., a hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence (should the participant become sexually active, she must agree to use a double-barrier method of contraception). A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral oophorectomy.
Women of childbearing potential who are unwilling to undergo a urine pregnancy test.
Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the Investigator, makes the participant unsuitable from an efficacy or safety perspective.
In the opinion of the Investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
Currently or in last 30 days, has been in a clinical trial involving another study drug.
Have donated blood or blood products within 30 days prior to study drug administration
Advanced renal impairment (serum creatinine >132 µmol/L) or a risk for renal failure due to volume depletion.
Severe known haemopoietic, renal or hepatic disease, or immunosuppressed, including any clinically significant finding from the laboratory tests results (biochemistry and hematology at screening), which, in the opinion of the Investigator, means that it would not be in the participants' best interests to participate in this study.
History of gastric ulceration or other GI disorders that, in the opinion of the Investigator make the participant unsuitable (e.g. frequent treatment of gastroesophageal reflux disease, inflammatory bowel disease, etc).
History of severe asthma in the opinion of the investigator.
Has a history of drug or alcohol abuse
Suffering from any other disease or condition which, in the opinion of the Investigator, means that it would not be in the participant's best interests to participate in this study.
Primary purpose
Allocation
Interventional model
Masking
180 participants in 3 patient groups
Loading...
Central trial contact
Laura Boddington
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal